Mark Chen

Mark Chen is a distinguished professional in the field of biomedical research and precision medicine, currently serving as the Global Biomarker Lead for the Precision Medicine Team at Amgen since November 2025. Prior experience includes holding the position of Associate Director at Takeda from June 2022 to 2024 and acting as Research Lead for the Non Alcoholic Steatohepatitis (NASH) program at Genentech from July 2012 to July 2022. Mark Chen also contributed as a Senior Scientific Researcher at FFA Sciences LLC in early 2012 and worked as a Scientist and Post Doctoral Fellow at UC San Diego from 2008 to 2011. Earlier academic experience includes serving as a Laboratory Technician at the University of Michigan's Department of Radiation Oncology from 2001 to 2003. Mark Chen earned a Ph.D. in Cell Signaling from UT Southwestern Medical Center (2003-2008) and a B.S. in Cell and Molecular Biology from the University of Michigan (1997-2001).